Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 – Clinical Trial Optional)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 16, 2026
Can you apply?
This grant is for researchers and institutions developing novel screening approaches, diagnostic tools, or therapies for newborn screening and detection of screenable genetic and metabolic disorders. Eligible applicants include NIH-grantee institutions, academic medical centers, research hospitals, and nonprofit organizations with research capacity. The program supports domestic projects, though some international collaboration may be permitted with appropriate justification. Funded activities include development and validation of innovative screening technologies, pilot clinical trials, translational research connecting laboratory discovery to clinical implementation, and feasibility studies. The grant typically supports early-stage research (R21 mechanism) with optional clinical trial components for testing new screening or therapeutic approaches in newborn populations.
Not the right fit? Find grants for your organization in 5 questions →
Program description
This FOA encourages research relevant to the development of novel screening approaches and/or therapeutic interventions for potentially fatal or disabling conditions that have been identified through newborn screening, as well as for “high priority” genetic conditions where screening may be possible in the near future.Having an accurate screening test, as well as demonstrating the benefits of early intervention or treatment, are important criteria for including a condition on a newborn screening panel. This FOA defines a “high priority” condition as one where screening is not currently recommended, but infants with the condition would significantly benefit from early identification and treatment.
Who can apply
Eligible applicants
- 501(c)(3) Public Charity
- City / Municipal Government
- County Government
- Nonprofits
- Private University
- Public Authority
- Public K-12 School
- Public University
- Small Business (SBA-defined)
- Special District
- State Government
- Tribal Nation
- Tribal Organization
Demographic focus
How to apply
Application links
Required documents
- NIH R21 Application Form (SF-424 R&R)
- Project Narrative (typically 15 pages maximum for research strategy)
- Specific Aims (1 page summary of research objectives)
- Research Strategy (including significance, innovation, and approach)
- Preliminary Data/Progress Report
- Biographical Sketches (PHS 398) of key personnel
- Budget and Budget Justification
- Current and Pending Support documentation
- Institutional commitment letter and IRB approval or IRB-exempt determination
- Letters of support if applicable (clinical partners, collaborating institutions)
Program contact
- 👤 National Institutes of Health
- 📧 grantsinfo@nih.gov
- 📞 301-402-2541
Funding track record
Recent awards under CFDA 93.865 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$1,073,967,938
-
$719,372,575
-
$276,059,721
-
$155,556,396
-
$155,482,198
-
$103,665,364
-
$74,151,078
-
$72,701,366
-
$52,238,426
-
$47,450,377
Top States by Funding
- WA 1 awards $1,074.0M
- NC 7 awards $925.9M
- MD 4 awards $501.6M
- MA 3 awards $190.0M
- PA 3 awards $145.1M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.865). How funding has trended year over year.
| 2024 | $1,282,226,682 | |
| 2025 | $1,333,391,690 | |
| 2026 est. | $184,920,723 |
FAQ
Who is eligible to apply for this R21 grant?
Research institutions, universities, medical centers, and nonprofit organizations with an active IRB and research infrastructure are eligible. Individuals must have a doctoral degree or equivalent and institutional affiliation. International institutions can apply if based at US-affiliated organizations.
What is the deadline and application timeline?
The fixed deadline is November 16, 2027. Applications open December 2, 2024. Most NIH grants have submission windows of several months before the deadline; plan accordingly to allow time for institutional review and submission.
What types of research activities are supported?
The program supports development of innovative screening tests, diagnostic tools, biomarkers, and therapies for newborn screening. Clinical trials are optional but permitted. Feasibility studies, pilot projects, and translational research connecting lab discovery to clinical application are encouraged.
How competitive is this funding and what is the typical award amount?
R21 grants are moderate-sized awards typically ranging from $150,000-$300,000 total costs over 2 years. Competition is substantial as this targets cutting-edge screening innovation. Success rates are typically 15-25% for NIH mechanisms. Strong preliminary data and clear innovation are critical.
What are the key review criteria?
Reviewers assess scientific innovation, significance to newborn health, feasibility and timeline realism, investigator qualifications, and institutional support. Clinical relevance and potential to improve screening practice matter substantially. For clinical trial components, study design and ethical considerations receive additional scrutiny.
💡 Tips for applicants
- Lead with innovation: Clearly articulate what is genuinely novel about your screening approach or therapy compared to existing methods. Reviewers expect paradigm shifts or significant improvements for R21 funding.
- Establish preliminary data: Even for early-stage work, include proof-of-concept results, pilot data, or strong supporting evidence from literature. R21s require demonstrated feasibility, not just ideas.
- Define the newborn population clearly: Specify which screenable disorders you target, current screening gaps, and how your approach addresses unmet clinical needs. Explain why innovation is needed now.
- Plan realistic timelines: R21s are 2-year awards. Ensure your research plan is achievable within this timeframe. Overly ambitious scope is a common rejection reason.
- Build in clinical translation pathway: Even if your current proposal focuses on development, articulate how results will move toward clinical application. NIH emphasizes real-world impact for newborn screening innovation.
⚠️ Common mistakes
Many applications fail because they lack sufficient preliminary data to demonstrate feasibility—R21s are early-stage but not unfounded. Another common issue is proposing improvements to existing screening that are incremental rather than innovative; reviewers expect meaningful advances. Additionally, poorly justified timelines that appear overstuffed for a 2-year award raise concerns about feasibility and reduce competitiveness.
Similar grants
- OPEN Innovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 – Clinical Trial Optional) — National Institutes of Health
- OPEN Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R34 Clinical Trial Optional) — National Institutes of Health
- OPEN Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional) — National Institutes of Health
- OPEN Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R21 Clinical Trial Not Allowed) — National Institutes of Health